Thermo Fisher Scientific Inc. (TMO) has seen a mixture of positive and negative performance in the stock market. While TMO has in some instances underperformed the market, it has also outpaced gains and shown resilience during economic headwinds. The stock has shown a consistent 17% CAGR over the last five years and demonstrated robust fundamentals. Its Q1 2024 earnings have exceeded expectations with an adjusted EPS that outperforms analyst expectations. Thermo Fisher has also indicated strategic growth by announcing a quarterly dividend and authorization of $4 billion in share repurchases. However, the stock is seen as a risky investment, with some investors decreasing their TMO holdings and the UK's CMA instigating a probe into Thermo Fisher's Olink deal. Despite periodic underperformance, TMO's stock has an attractive intrinsic value and has displayed healthy financials driving a recent rally. Yet, there are concerns about TMO's debt and the company's projected 2024 demand. TMO plans to present at the BofA Securities 2024 Health Care Conference and has launched a new CXCL10 testing service.
Thermo Fisher Scientific TMO News Analytics from Tue, 12 Sep 2023 07:00:00 GMT to Wed, 29 May 2024 20:35:00 GMT -
Rating 3
- Innovation -1
- Information 5
- Rumor -3
